Clinical Trial Update: Extension Study of Subcutaneous Immunoglobulin Human in Patients With Primary Immunodeficiency (PID) [Phase 3]

View source ↗

Summary

This Phase 3 extension study of subcutaneous immunoglobulin in patients with primary immunodeficiency has completed, and results were posted in 2013.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immunodeficiency

Drugs mentioned

• Hizentra (subcutaneous immunoglobulin (IgG))

Snippet

Sponsor: CSL Behring | Conditions: Primary Immune Deficiency | Phase 3 | Status: COMPLETED | Results posted: 2013-01-25